Literature DB >> 9174605

Signals through CD8 or CD4 can induce commitment to the CD4 lineage in the thymus.

U Bommhardt1, M S Cole, J Y Tso, R Zamoyska.   

Abstract

Differentiation of thymocytes into mature single-positive T cells is an ordered process involving sequential interactions between T cell receptor (TCR), co-receptors (CD4 or CD8) and their appropriate major histocompatibility complex-encoded ligands. Precisely how these receptor/co-receptor engagements determine lineage commitment is still controversial, but recently it has been suggested that quantitative differences in the signal transmitted by co-ligation of CD4 versus CD8 with TCR might provide the discriminating signal. We examine this hypothesis, using bispecific F(ab')2 antibodies to mimic TCR/ co-receptor engagement during thymocyte differentiation. These bispecific antibodies lack Fc and can engage surface molecules without extensive cross-linking or targeting to Fc receptor-bearing cells. We show that TCR/CD3 co-ligation with CD4 induces efficient differentiation of mature CD4 lineage cells, irrespective of their TCR specificity. Interestingly, TCR/CD3 co-ligation with CD8 also induces maturation of CD4 T cells, although less efficiently, but not of CD8 T cells. Thus, although the signals delivered by co-ligation of TCR and CD8 appear weaker than from co-ligation of TCR and CD4, the outcome from either engagement is the same. These data suggest that differences in signal intensity alone do not determine lineage commitment in the thymus, but that distinct signals are required for CD4 and CD8 single-positive cell differentiation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9174605     DOI: 10.1002/eji.1830270516

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

Review 1.  Ligand-dependent regulation of T cell development and activation.

Authors:  Ronald N Germain
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

2.  Thymic myoid cells protect thymocytes from apoptosis and modulate their differentiation: implication of the ERK and Akt signaling pathways.

Authors:  R Le Panse; S Berrih-Aknin
Journal:  Cell Death Differ       Date:  2005-05       Impact factor: 15.828

3.  Adaptive immune responses during Shigella dysenteriae type 1 infection: an in vitro stimulation with 57 kDa major antigenic OMP in the presence of anti-CD3 antibody.

Authors:  Ashim Kumar Bagchi; Ajoy Kumar Sinha; Rushita Adhikari; Joydeep Mukherjee
Journal:  Mol Cell Biochem       Date:  2009-11-14       Impact factor: 3.396

4.  Receptor avidity and costimulation specify the intracellular Ca2+ signaling pattern in CD4(+)CD8(+) thymocytes.

Authors:  B D Freedman; Q H Liu; S Somersan; M I Kotlikoff; J A Punt
Journal:  J Exp Med       Date:  1999-10-04       Impact factor: 14.307

5.  How many thymocytes audition for selection?

Authors:  M Merkenschlager; D Graf; M Lovatt; U Bommhardt; R Zamoyska; A G Fisher
Journal:  J Exp Med       Date:  1997-10-06       Impact factor: 14.307

6.  An antagonist peptide mediates positive selection and CD4 lineage commitment of MHC class II-restricted T cells in the absence of CD4.

Authors:  Henry Kao; Paul M Allen
Journal:  J Exp Med       Date:  2005-01-03       Impact factor: 14.307

7.  CD3 ligation on immature thymocytes generates antagonist-like signals appropriate for CD8 lineage commitment, independently of T cell receptor specificity.

Authors:  M A Basson; U Bommhardt; M S Cole; J Y Tso; R Zamoyska
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

8.  Visualization of CD4/CD8 T cell commitment.

Authors:  S Chan; M Correia-Neves; A Dierich; C Benoist; D Mathis
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

9.  Antagonist peptide selects thymocytes expressing a class II major histocompatibility complex-restricted T cell receptor into the CD8 lineage.

Authors:  A Volkmann; T Barthlott; S Weiss; R Frank; B Stockinger
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.